BRCA2 and Familial prostate cancer: In conclusion, this unicentric analysis of BRCA1/2 and HRR gene mutations in prostate cancer, analyzed over a 5-year period, found a lower prevalence of BRCA2 mutations than previously reported: only 4.9% are deemed eligible for olaparib treatment as per EMA approval.